Digoxin and Senolysis in Heart Failure and Diabetes Mellitus

In pilot studies the investigators have shown that subcutaneous adipose tissue (SAT) from patients with reduced ejection fraction heart failure (HFrEF) and type 2 diabetes mellitus (T2DM) is dysfunctional. Endothelial cells from the adipose tissue from these patients are senescent and have deleterious effects on healthy human subcutaneous adipocytes, including increasing expression of IL-6 (gene and protein) and reducing glucose uptake. Digoxin, a well-established treatment for HFrEF, selectively clears these senescent endothelial cells and prevents adipocyte dysfunction. This study will examine the effect of digoxin on adipose tissue on the burden of senescent cells.

NCT Number	NCT06240403
Lead Sponsor	University of Leeds
Conditions	Heart Failure, Systolic, Diabetes Mellitus, Type 2
Enrollment	100 participants
Start Date	2025-09-01
Primary Completion	2028-08-28 (estimated)
Study Completion	2029-08-28 (estimated)
Updated on ClinicalTrials.gov	2024-12-06